China NMPA Inspection - Anhui Telunshak Biotechnology Research Co., Ltd. - January 09, 2026

The National Medical Products Administration (NMPA) recently conducted a surprise inspection of Anhui Telunshake Biotechnology Research Co., Ltd., with results announced on January 9, 2026. The inspection revealed serious deficiencies within the company's production quality management system. Specifically, Anhui Telunshake Biotechnology Research Co., Ltd. was found to be in violation of key regulatory frameworks, including the "Cosmetics Supervision and Management Regulations" and the "Cosmetics Production Quality Management Standards." These breaches indicate a failure to adhere to established national standards for the production and management of cosmetics, posing potential risks to public safety. In response to these findings, the NMPA has mandated immediate and stringent actions. The Anhui Provincial Drug Administration has been instructed to launch a formal investigation into the company's suspected illegal activities and to enforce appropriate penalties as per legal provisions. Furthermore, Anhui Telunshake Biotechnology Research Co., Ltd. has been ordered to suspend all production and operational activities and to promptly rectify the identified systemic issues. This regulatory intervention underscores the NMPA's commitment to ensuring the safety and quality of cosmetic products available to the public. The investigation is currently underway, and the company is required to address all deficiencies before resuming operations.